Trial · NCT04139213
Medication Maintenance Therapy in Community Pharmacy Settings
NCT04139213, Phase 2, Phase 3, Unknown, Lifespan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Medication Maintenance Therapy in Community Pharmacy Settings. Trials, record NCT04139213. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04139213
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Medication Maintenance Therapy in Community Pharmacy Settings
- NCT number
- NCT04139213
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Lifespan
- Conditions
- Opioid-use Disorder
- Interventions
- buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care, oral naltrexone
- First posted
- 2019-10-25
- Last updated
- 2022-08-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Retention in MAT | up to 90 days post randomization | Proportion of patients attending one or more visits with MAT providers every 30 days for up to 90 days post randomization according to the medical or pharmacy record |
| Primary | Relapse to drug use | up to 90 days post randomization | Proportion of patients who relapse to drug use, defined as absence of the MAT medication and presence of heroin or other illicit opioids. Measured by toxicological (urine or oral) analysis, with samples collected at every visit (i.e., \<every 30 days), or at the 3-month interview at the research site. For patients attending visits, the toxicological results will consider those in the medical or pharmacy record. Urine or oral samples will test for drugs of abuse plus fentanyl, using a rapid qualitative immunoassay. |
| Secondary | Primary care visits | up to 90 days post randomization | Measured by patient self-report, patient medical record review, or by direct contact with the facility, clinician, or both. The self report item asks: How many times did you visit your primary care provider (do NOT count visits to providers at the emergency department) in the past 90 DAYS (since starting this study)? 1. Never, no provider 2. Never, but I have a provider 3. Once or twice 4. 3-5 times 5. 6 or more times |
| Secondary | Emergency department visits | up to 90 days post randomization | Measured by patient self-report, patient medical record review, or by direct contact with the facility, clinician, or both. The self report item asks: How often did you visit the emergency room in the past 90 DAYS (since starting this study)? 1. Never 2. Once or twice 3. 3-5 times 4. 6 or more times |
| Secondary | Hospitalizations | up to 90 days post randomization | Measured as by patient self-report, patient medical record review, or by direct contact with the facility, clinician, or both. The self report item asks: How often were you hospitalized in the past 90 DAYS (since starting this study)? 1. Never 2. Once or twice 3. 3-5 times 4. 6 or more times |
| Other | Engagement in MAT | up to 30 days post randomization | Proportion of patients with one or more visits during the first 30 days post randomization according to the medical or pharmacy record |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36630629 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04139213
GET https://conductscience.org/api/trials/v1/NCT04139213/registered